HSK31679 clinical trials
Also written HSK31679.
How each study uses HSK31679 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HSK31679 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HSK31679
- 2
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Haisco Pharmaceutical Group Co., Ltd. (4) · Xizang Haisco Pharmaceutical Co., Ltd (1)
Studies
Open first, then newest update. How each study uses HSK31679 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASHRecruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07581951Written as HSK31679
- To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .CompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06168383Written as HSK31679 80mg
- Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK31679 in Healthy Adult Male Volunteers.Active, not recruitingPhase 1Xizang Haisco Pharmaceutical Co., LtdNCT06258746Written as [14C]HSK31679
- Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)CompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT05795517Written as HSK31679 low dose
- Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-CCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT05531097Written as HSK31679